LY 163892

Known as: LY-163892, LY163892 
 

Topic mentions per year

Topic mentions per year

1987-1995
01219871995

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Sputum and serum pharmacokinetics of loracarbef (LY163892) were performed in 19 patients with purulent bronchiectasis. Nine of… (More)
Is this relevant?
1992
1992
Loracarbef (LY 163892), a beta-lactam antibiotic (carbacephem), was compared with amoxicillin/clavulanate potassium in a 10-day… (More)
Is this relevant?
1992
1992
In this single-blind study, 579 patients with chronic bronchitis were randomly assigned to receive 400 mg of loracarbef twice… (More)
Is this relevant?
1992
1992
A double blind, randomized clinical trial compared loracarbef (LY163892) with penicillin VK. Two hundred thirty-three pediatric… (More)
Is this relevant?
1988
1988
LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and… (More)
Is this relevant?
1988
1988
The in vitro activity of LY163892, a synthetic oral cephalosporin, was compared with those of cefaclor and cefuroxime against 1… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
1988
1988
The in-vitro activity of a new oral carbacephem, LY163892, was compared with cefaclor, cephalexin, cephradine, cefadroxil and… (More)
Is this relevant?
1988
1988
Two dosages (7.5 and 15 mg/kg of body weight) of LY163892 were given to infants and children, and five plasma specimens were… (More)
  • table 1
  • table 2
Is this relevant?
1988
1988
LY163892 was found to be similar to cefaclor and slightly superior to cephalexin in antimicrobial activity and spectrum. Bacteria… (More)
Is this relevant?
1988
1988
Susceptibility testing of clinical isolates of several gram-negative and gram-positive species showed LY163892 to be more active… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?